ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases.
Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease.
Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.
Company Details
- Employees
- 12
- Founded
- -
- Address
- 2200 N. Commerce Parkway, Suite 208, Weston,fl 33326,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- zyversa.com
- HQ
- Weston, FL
Zyversa Therapeutics Inc. Questions
Zyversa Therapeutics Inc.'s website is zyversa.com
Zyversa Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/zyversa.com
Zyversa Therapeutics Inc. has
12 employees.
View email and phone details for 12
employees at Zyversa Therapeutics Inc..
Zyversa Therapeutics Inc.'s industry is
Pharmaceutical Manufacturing
Zyversa Therapeutics Inc.'s top competitors are
Marvel Biosciences Corp.,
Tango Therapeutics,
Kbi Biopharma,
Merida Biosciences,
Rhythm Pharmaceuticals Inc.,
Jazz Pharmaceuticals,
Tempest Therapeutics,
Mylan,
Rallybio,
Zevra Therapeutics.
Zyversa Therapeutics Inc.'s categories are Pharmaceutical Manufacturing
Zyversa Therapeutics Inc.'s founding year is 2014
